Clinical trial
A Double-Blind, Randomized, Controlled, Phase 3 Study to Evaluate the Safety and Immunogenicity of CpG 1018/Alum-adjuvanted SCB-2019 in Individuals Aged 18 and Above With Chronic Immune-Mediated Inflammatory Diseases
NCT05012787 is registered in ClinicalTrials.gov with Clover Biopharmaceuticals AUS Pty as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Randomized, Controlled, Phase 3 Study to Evaluate the Safety and Immunogenicity of CpG 1018/Alum-adjuvanted SCB-2019 in Individuals Aged 18 and Above With Chronic Immune-Mediated Inflammatory Diseases
- Lead sponsor
- Clover Biopharmaceuticals AUS Pty
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- November 12, 2021
- Completion date
- May 4, 2022
- Enrollment
- 1 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.